These Chinese medicine tablets are prohibited from production and sale.

On June 19, the Yunnan Provincial Drug Administration issued a notice on the filing of chinese medicine tabletsaccording to the notice, All Chinese medicine tablet enterprises in Yunnan Province should be in accordance with the requirements for the filing proceduresspecific requirements are as follows:apply to start a chinese medicine tablet production enterprise, in the "drug production license" declaration materials should provide all the proposed production of Chinese medicine drink tablet sliver catalog;after passing the GMP compliance check, the new Chinese medicine drink inge varieties produced (except for the net system, cut The variety of Chinese medicine drink tablets), shall be in accordance with the requirements for the filing proceduresnotice clearly requires that, in accordance with the "Yunnan Food and Drug Administration on the implementation of the newly promulgated Chinese medicine tabletappendix related issues" (Cloud Food and Drug Administration (2014) No59) provisions, in the original state, municipal Food and Drug Administration for the record of the implementation of the statutory standards of the Chinese medicine tablet varieties continue to be effective If an enterprise acquires a production license a new variety of Chinese medicine drink tablets that has not been filed, the variety has been filed but the implementation standard does not meet the statutory requirements, the implementation standard has been revoked, or if the enterprise's production address changes, it shall re-record before December 31, 2020As of January 1, 2021, the chinese medicine tablets that enterprises have not gone through the filing procedures shall not be produced and sold on the marketChinese medicine tablets, more and more difficult torecently, there is news that the "Chinese Pharmacopoeia" 2020 version of the paper version has been officially releasedit is understood that the Chinese Pharmacopeia is the core of China's drug standards system, is the legal basis for drug research, production, operation, use and supervisionThe 2020 edition of pharmacopeia has become the focus of high attention in the industry because of the improvement of standards for heavy metals and agricultural residues inspection of Chinese herbal medicinesis understood that the 2020 edition of the Pharmacopoeia for plant-type Chinese herbal medicines, will be comprehensive to check heavy metals and harmful elements limitsIn addition, 33 banned pesticides are not detectedthat is, with the implementation of the 2020 edition of the Pharmacopoeia, Chinese medicine enterprises will face the high standards of heavy metal, agricultural residues testing requirements, enterprise hardware must be upgraded, with the increase in costsin addition, it has been reported that the State Drug Administration recently held a teleconference to summarize the 2019 Chinese medicine tablets concentrated rectification work and the 2020 Chinese medicine tablets special rectification work to do deployment and mobilizationspecial rectification activities of Chinese medicine tablets, is one of the four special rectification activities in the 2020 work plan of the State Drug Administration for drug safety supervision, and in February this year, the Special Work Programme for the Special Rectification of Chinese Medicine Drink Tablets was issued, which put forward the overall objectives and key points of work for the special rectification workin accordance with the unified deployment of the State Drug Administration, provinces and cities have issued a letter to start the special rectification of Chinese medicine tabletsSaei-Lan combing found that at present, Jiangsu, Hunan, Guizhou, Hainan, Jiangxi, Hubei, Anhui, Jiangsu and many other places have also introduced a special work programme for Chinese medicine tabletswith the strict inspection of the State Drug Administration, the implementation of the newly revised Drug Administration Law, coupled with the high standards of the 2020 edition of the Pharmacopoeia, for Chinese medicine enterprises, it is impossible to rely on the production of counterfeiting, record fraud, even laboratory testing orders are false to continue to surviveAccording to the newly revised Drug Administration Law, once the major problems of enterprises are found, each time a fine of 1.5 million yuan to start, and even serious cases have the potential risk of the license to be revoked at any time, such punishment is most of the Chinese medicine tablets enterprises are unbearableunder the high requirements, will force the drinking film industry to eliminate backward production capacityRelated Chinese medicine drink tablets enterprises if now can not follow up in time or prepare for the rain, it will be very difficult to survive.